Understanding the disease landscape and the competitive clinical trial environment when positioning a new clinical trial within the rare disease space.
PRA Successfully Rescues Phase II Hematology Study
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to…
How Do Patients Get a Seat at the Drug Development Table?
RARE DISEASES NEWSLETTER Volume 5, January 2017
This quarterly publication will keep you up to date on PRA’s Rare Disease Team focus, achievements, and new initiatives.